Category: Thomson Reuters
Venture capital investors spent 21% more backing life science startups in 2011 than in 2010, according to PricewaterhouseCoopers; also, VCs in the Valley lose confidence; Greenway Medical prices IPO; does Abbott need a new CEO?; and analysts' ups and downs.
Venture capital funding of life science startups, including biotech and medical device enterprises, rose by 21% last year, according to PricewaterhouseCoopers.
VCs dropped $7.5 billion on 785 life sciences deals during the year, according to a PwC report, "Zigzagging Upward," compiled using data from the PricewaterhouseCoopers LLP/National Venture Capital Assn. MoneyTree Report and Thomson Reuters.
